Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0VYKSA
ADC Name	LM-305
Synonyms	LM 305; LM305 Click to Show/Hide
Organization	LaNova Medicines Ltd.; AstraZeneca PLC
Drug Status	Phase 1/2
Indication	In total 2 Indication(s) Multiple myeloma [ICD11:2A83] Phase 2 Solid tumors [ICD11:2A00-2A0Z\|2B50-2F9Z] Phase 1
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	G-protein coupled receptor family C group 5 member D (GPRC5D)		Antigen Info
Payload Name	Monomethyl auristatin E		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 100	%	Multiple myeloma cells	Multiple myeloma

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	0.10-0.30	nM	NCI-H929 cells	Plasma cell myeloma
Half Maximal Inhibitory Concentration (IC50)	0.10-0.30	nM	MM1.R cells	Plasma cell myeloma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00%	High GPRC5D expression (GPRC5D+++)
Method Description	The inhibitory activity of LM-305 against cancer cell growth was evaluated in Multiple myeloma CDX model in vivo. The dose of LM-305 was 3 mg/kg.
In Vivo Model	Multiple myeloma CDX model
In Vitro Model	Multiple myeloma	Multiple myeloma cells		Homo sapiens

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10-0.30 nM	High GPRC5D expression (GPRC5D+++)
Method Description	LM-305 was evaluated in vitro for its cytotoxic activity against a panel of multiple myeloma cell lines. LM-305 was co-cultured with multiple myeloma cells.
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10-0.30 nM	High GPRC5D expression (GPRC5D+++)
Method Description	LM-305 was evaluated in vitro for its cytotoxic activity against a panel of multiple myeloma cell lines. LM-305 was co-cultured with multiple myeloma cells.
In Vitro Model	Plasma cell myeloma	MM1.R cells		CVCL_8794

References

Ref 1	Preclinical activity of LM-305 targeting G-protein-coupled receptor class 5 member D (GPRC5D) antibody drug conjugate for the treatment of multiple myeloma. Cancer Res (2022) 82 (12_Supplement): 6020.